Board of Directors

Aditya Puri, Investments Director at Xeraya Capital, Board Member

Aditya Puri is an Investments Director at Xeraya Capital, which is responsible for life sciences investments for Khazanah Nasional Berhad, the Malaysian government’s strategic investment fund.  He joined Khazanah Nasional’s Life Sciences team after moving from the greater Boston area where he was working with Healthcare and Cleantech startups affiliated with Harvard and MIT.  He has more than 20 years of experience and leadership encompassing general management, private equity and venture investments, and international expansion across life science and technology industries.  His prior experience includes P&L responsibility and leadership positions at Yankee Group, a global technology research and consulting company, and Corporate Development at Boston Scientific, a Fortune 500 medical device manufacturer.  He serves on boards of public and private Life Sciences companies in the US, and private companies abroad.  He received his B.S. from the University of Southern Maine, graduating Summa Cum Laude, and his MBA from the MIT Sloan School of Management. He has also passed all parts of the U.S. Uniform CPA Examination.


Aloyzas Petrikas, Chairman.

Al Petrikas is a successful entrepreneur. An American citizen, he founded and lead several companies, including Vitta Corporation.   He has more than 30 years of management experience in product development.  He has served on the Board of Directors of the Connecticut Business and Industry Association and also the Fairfield County Business Development Board.


T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd, Board Member

Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital.  Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen’s University Belfast.  He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons.  He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds.  He received an AB from Columbia, and an MD and MPH from Johns Hopkins.  He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen’s University Belfast for contributions to medicine and public service. 


Christopher Hunt, COO Imprimatur Capital Limited, Board Member

Christopher founded Fair-Lead Partners which was a FCA regulated boutique advisory firm, in 2009 after a seventeen year career with blue chip Investment banks, predominantly in Asia. As a Managing Director and Head of Asian Equities, at Cazenove Asia, Christopher was responsible for the regulatory operation of the platform, with ninety research, sales and trading staff in five global locations. He had operational oversight of the business and was an integral part of the sale of Cazenove Asia to Standard Chartered Bank. Previously, he was an Executive Director of Equity Capital Markets (ECM) and Global Head of Asian Equity Syndicate at Morgan Stanley Asia. He has extensive experience in ECM transactions, Initial Public Offerings and allocations and operational risk.